Drug Trial Radar · NCT06552169
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
34
Planned (sponsor's estimate)
Start
Jun 13, 2025
Primary completion
Dec 2027
Study completion Dec 2031
Sponsor
- Lead sponsor
- Singulera Therapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Taiwan Bio Therapeutics Inc.
- First posted
- Aug 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients. Enrolled subjects will be randomized to one of 2 study arms: Arm 1 subjects will receive standard of care immunosuppression Arm 2 subjects will receive initial standard of care (SOC) immunosuppression and a single infusion of TRK-001. Three months after the transplant, Arm 2 subjects may be able to begin reducing their immunosuppression medication to a 1-drug regimen. The primary outcome measures of trial are to evaluate several components indicating immunologic problems with the transplanted organ at 1-year post-transplant and to evaluate the ability for the study subjects given TRK-001 to wean to a 1-drug immunosuppression regimen. All enrolled subjects will be followed for 5 years post-transplant.
Conditions
- Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI)Drug
Subjects randomized to Arm 1 will remain on standard dual-immunosuppression therapy (CNI and mTOR) throughout the trial.
Arm 2A: TRACT/MONO mTORBiological
All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either: * Arm 2A: mTOR monotherapy or * Arm 2B: CNI monotherapy. These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant. Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product.
Arm 2B: TRACT/MONO CNIBiological
All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either: * Arm 2A: mTOR monotherapy or * Arm 2B: CNI monotherapy. These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant. Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development of de novo donor-specific antibodiesTime frame: Month 12 Post-transplant
- Biopsy-proven acute rejectionTime frame: Month 12 Post-transplant
- Biopsy-proven subclinical rejectionTime frame: Month 12 Post-transplant
- Development of significant (2+) interstitial fibrosis/tubular atrophyTime frame: Month 12 Post-transplant
- Successful taper to monotherapy (Arm 2)Time frame: Month 12 Post-transplant
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Phoenix, Arizona · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
Mayo Clinic in Minnesota
Rochester, Minnesota · Recruiting
Taichung Veterans General Hospital
Taichung, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Chang Gung Medical Foundation Hospital
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.